Jagsonpal Pharmaceuticals completes 77.21% acquisition of Aequitas Healthcare

What Jagsonpal Pharmaceuticals announced

Jagsonpal Pharmaceuticals Ltd filed a general‑updates notice with the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) on 8 July 2026. The filing confirms that the company has completed the acquisition of a 77.21% equity stake in Aequitas Healthcare Private Limited. Earlier correspondence dated 29 June 2026 and 7 July 2026 had indicated a plan to acquire 85% of Aequitas. The new filing updates the market on the actual percentage secured.

"Against the proposed acquisition of 85% equity stake in Aequitas, the Company has completed the acquisition of 77.21% equity stake."

The notice was submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Details of the acquisition

• Target entity: Aequitas Healthcare Private Limited (referred to as “Aequitas”).
• Original proposal: 85% equity stake, disclosed in letters dated 29 June 2026 and 7 July 2026.
• Completed stake: 77.21% equity stake, as of the filing date.
• Financial terms: The filing does not disclose the purchase price, consideration, or any related financing arrangements.
• Regulatory filing: The update was filed with both BSE and NSE on 8 July 2026, referencing the earlier letters and complying with SEBI’s disclosure requirements.

Key facts at a glance

Why this matters for investors

The acquisition gives Jagsonpal Pharmaceuticals majority control over Aequitas Healthcare, potentially expanding its footprint in the healthcare services segment. Since the filing does not disclose the transaction value, investors cannot assess immediate dilution or cash outflow effects. However, the shift from an 85% to a 77.21% stake may reflect negotiations, regulatory considerations, or financing constraints. The filing does not mention any pending approvals, but standard post‑closing compliances—such as competition clearance or board ratification—may still apply.

Conclusion

Jagsonpal Pharmaceuticals has formally recorded the completion of a 77.21% equity acquisition in Aequitas Healthcare, updating its earlier intention to acquire 85% of the company. While the financial details remain undisclosed, the filing satisfies SEBI’s disclosure obligations and provides shareholders with a clear picture of the ownership change. Further information, if any, will likely emerge in subsequent filings or board communications.